Evidence map›Paper›PMID 36551928›Full record

ArticleBiomedicines2022

A Missense Variant in

Raquel Vaz, Josephine Wincent, Najla Elfissi, Kristina Rosengren Forsblad, Maria Pettersson, Karin Naess, Anna Wedell, Anna Wredenberg, Anna Lindstrand, Sofia Ygberg

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Targeting the PDK1/c-Myc/SOX10 Signaling in Oligodendrocytes Alleviates Neuropathic Pain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Raquel VazDepartment of Molecular Medicine and Surgery, Karolinska Institute, 17177 Stockholm, Sweden.ORCID 0000-0001-7518-1801
Josephine WincentDepartment of Molecular Medicine and Surgery, Karolinska Institute, 17177 Stockholm, Sweden.
Najla ElfissiDepartment of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden.
Kristina Rosengren ForsbladAkademiska Sjukhuset, 75185 Uppsala, Sweden.
Maria PetterssonDepartment of Molecular Medicine and Surgery, Karolinska Institute, 17177 Stockholm, Sweden.
Karin NaessCentre for Inherited Metabolic Diseases, Karolinska University Hospital, 17177 Stockholm, Sweden.
Anna WedellDepartment of Molecular Medicine and Surgery, Karolinska Institute, 17177 Stockholm, Sweden.
Anna WredenbergDepartment of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden.
Anna LindstrandDepartment of Molecular Medicine and Surgery, Karolinska Institute, 17177 Stockholm, Sweden.ORCID 0000-0003-0806-5602
Sofia YgbergDepartment of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden.
Karolinska University Hospital · SEKarolinska Institutet · SEUppsala University Hospital · SE

Funding

Föreningen Margarethahemmet n/aKarolinska Institutet Research Foundation Grant 2022-01896Knut and Alice Wallenberg Foundation KAW2019.0109Novo Nordisk Foundation NNF18OC0032200Stockholm Regional Council n/aSwedish Brain Foundation FO2020-0351Swedish Rare Diseases Research Foundation n/aSwedish Research Council VR2019-02078 and VR2016-02179
6 · The paper itself

Abstract

The pyruvate dehydrogenase complex (PDC) is responsible for the conversion of pyruvate into acetyl-CoA, which is used for energy conversion in cells. PDC activity is regulated by phosphorylation via kinases and phosphatases (PDK/PDP). Variants in all subunits of the PDC and in PDK3 have been reported, with varying phenotypes including lactic acidosis, neurodevelopmental delay, peripheral neuropathy, or seizures. Here, we report a de novo heterozygous missense variant in PDK1 (c.1139G > A; p.G380D) in a girl with developmental delay and early onset severe epilepsy. To investigate the role of PDK1G380D in energy metabolism and neuronal development, we used a zebrafish model. In zebrafish embryos we show a reduced number of cells with mitochondria with membrane potential, reduced movements, and a delay in neuronal development. Furthermore, we observe a reduction in the phosphorylation of PDH-E1α by PDKG380D, which suggests a disruption in the regulation of PDC activity. Finally, in patient fibroblasts, a mild reduction in the ratio of phosphorylated PDH over total PDH-E1α was detected. In summary, our findings support the notion that this aberrant PDK1 activity is the cause of clinical symptoms in the patient.

Indexed as

epilepsyneurodevelopmental delaypyruvate dehydrogenase kinasezebrafish

Identifiers

PMID36551928
PMCPMC9775741
OpenAlexW4311951229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.